摘要
美泊利单抗是由葛兰素史克公司研发的一种人源化抗IL-5单克隆抗体,现已经申请上市。第二、三期的临床试验已证实,美泊利单抗能特异结合IL-5,对严重难治性嗜酸粒细胞性哮喘有疗效。美泊利单抗的研究将为哮喘治疗带来新的前景。
Mepolizuma, a humanized interleukin 5 monoclonal antibodies developed by Glaxosmithkline, is now applying for the market. The recent clinical trials have been confirmed that the mepolizuma specifically targeted in interleukin 5, for the treatment of severe refractory eosinophilia asthma had curative effect. Researches for mepolizuma or will bring new prospect in the treatment of asthma.
出处
《国际呼吸杂志》
2016年第13期994-997,共4页
International Journal of Respiration